Last updated: 2026-09-07 15:42:20. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Phathom Pharmaceuticals, Inc. (PHAT) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $9.51, with a market capitalization of $768.56M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $8.21 to $18.31. This page covers its latest market performance, valuation, price trends and company information.
$768.56M | |
$8.99 | |
$64.54 | |
$2.21 | |
$9.05 | |
1.12M | |
1.26M | |
-- | |
$18.31 | |
$8.21 | |
-- | |
-- |
Phathom Pharmaceuticals, Inc. (PHAT) last closed at $9.05 as of 2026-09-04 23:45:00, unchanged from the previous close of $9.05.
During the latest regular trading session, PHAT traded between $2.21 and $64.54, with a volume of 1.12M shares. The closing price was near the lower end and near the lower end of its 52-week range.
Over the past seven days, Phathom Pharmaceuticals, Inc. (PHAT) moved from $8.94 to $9.51, representing a gain of 6.32% ($0.57).
The stock traded between $8.55 and $9.73 during the period. The latest price is near the upper end of the 7-day range, indicating strong upward.
The average daily volume was 981.56 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 12.8%
PHAT is currently trading at $9.51, placing it 12.8% of the way from its 52-week low of $8.21 to its 52-week high of $18.31. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 371 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Phathom Pharmaceuticals, Inc. (PHAT) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.